P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer

M. Zaleski; S. Sharzehi; R. Voland; J. Varlotto; N. Rassaei; Y. Liu

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer

【24h】

P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer

机译：P3.09-07糖尿病患者中编程死亡配体1的免疫组化表达与非小细胞肺癌的非糖尿病患者

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
M. Zaleski; S. Sharzehi; R. Voland; J. Varlotto; N. Rassaei; Y. Liu;
展开▼
作者单位

Pathology Penn State Health M.S. Hershey Medical Center Hershey;

Pathology Penn State Health M.S. Hershey Medical Center Hershey;

University of Wisconsin Madison;

Radiation Oncology University of Massachusetts Sudbury;

Penn State Hershey Medical Center Hershey;

Penn State Hershey Medical Center Hershey;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer [J] . M. Zaleski, S. Sharzehi, R. Voland, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P3.09-07糖尿病患者中编程死亡配体1的免疫组化表达与非小细胞肺癌的非糖尿病患者
2. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis [J] . Ma Guangzhi, Deng Yunfu, Jiang Hai, Clinica chimica acta: International journal of clinical chemistry and applied molecular biology . 2018,第期

机译：编程细胞死亡 - 配体1在非小细胞肺癌患者中表达的预后作用：更新的荟萃分析
3. PROGRAMMED CELL DEATH-LIGAND 1 EXPRESSION AND IMMUNOSCORE IN STAGE II AND III NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY [J] . Ishii Hidenobu, Azuma Koichi, Naito Yoshiko, Respirology : . 2017,第Suppla3期

机译：编程的细胞死亡 - 配体1在II期和III期非小细胞肺癌患者接受佐剂化疗的表达和免疫综合
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression [O] . Roy Herbst, Jacek Jassem, Seye Abogunrin, 2021

机译：癌症免疫治疗患者的癌症免疫治疗非小型细胞肺癌患者的网络荟萃分析高编程死亡 - 配体1表达
7. Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy [O] . Umberto Malapelle, Antonino Iaccarino, Antonio Rossi 2018

机译：细胞学与编程死亡配体1的组织学，非小细胞肺癌患者免疫疗法景观中的表达评价

P3.09-07 Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer

著录项

相似文献

相关主题

期刊订阅